Abeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations
May 03, 2016 08:03 ET
|
Abeona Therapeutics
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - May 03, 2016) - Abeona Therapeutics Inc (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering products for severe and...
Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting
April 15, 2016 08:03 ET
|
Abeona Therapeutics
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - April 15, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing and delivering gene...
Abeona Therapeutics to Present at Alliance of Regenerative Medicine's (ARM) 4th Annual Cell & Gene Therapy Investor Day
March 21, 2016 09:03 ET
|
Abeona Therapeutics
NEW YORK, NY AND CLEVELAND, OH--(Marketwired - March 21, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and...
Abeona Therapeutics to Present at the 28th Annual ROTH Conference
March 10, 2016 09:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH --(Marketwired - March 10, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and...
Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights
March 08, 2016 09:23 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - March 08, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and...
Abeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium(TM) 2016
March 02, 2016 08:19 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - March 02, 2016) -
AB0-201 (AAV CLN3) demonstrates promising in vivo efficacy in preclinical models
...
Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
February 29, 2016 07:03 ET
|
Abeona Therapeutics
NEW YORK, NY and CLEVELAND, OH--(Marketwired - February 29, 2016) -
Phase 1/2 dose escalation study of ABO-102 in 6-9 patients
Natural history study in 25 patients establishes...
Abeona Therapeutics, Inc. to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress
February 24, 2016 09:36 ET
|
Abeona Therapeutics, Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - February 24, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and...
Abeona Therapeutics to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
February 09, 2016 09:17 ET
|
Abeona Therapeutics
DALLAS, TX and NEW YORK, NY--(Marketwired - February 09, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and...
Abeona Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
February 04, 2016 09:28 ET
|
Abeona Therapeutics, Inc.
DALLAS, TX and NEW YORK, NY--(Marketwired - February 04, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and...